News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
739,144 Results
Type
Article (41774)
Company Profile (306)
Press Release (697048)
Multimedia
Podcasts (92)
Webinars (20)
Section
Business (207234)
Career Advice (2045)
Deals (35906)
Drug Delivery (130)
Drug Development (82600)
Employer Resources (175)
FDA (16557)
Job Trends (15121)
News (350709)
Policy (32958)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2604)
Accelerated approval (48)
Adcomms (26)
Allergies (172)
Alliances (50233)
ALS (213)
Alzheimer's disease (1809)
Antibody-drug conjugate (ADC) (453)
Approvals (16956)
Artificial intelligence (675)
Autoimmune disease (298)
Automation (57)
Bankruptcy (362)
Best Places to Work (11736)
BIOSECURE Act (20)
Biosimilars (227)
Biotechnology (201)
Bladder cancer (197)
Brain cancer (73)
Breast cancer (759)
Cancer (5873)
Cardiovascular disease (487)
Career advice (1735)
Career pathing (43)
CAR-T (335)
CDC (56)
Celiac Disease (3)
Cell therapy (910)
Cervical cancer (47)
Clinical research (71792)
Collaboration (2101)
Company closure (5)
Compensation (1421)
Complete response letters (80)
COVID-19 (2754)
CRISPR (108)
C-suite (1151)
Cystic fibrosis (154)
Data (7995)
Decentralized trials (3)
Denatured (28)
Depression (165)
Dermatology (87)
Diabetes (588)
Diagnostics (6951)
Digital health (55)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (324)
Drug pricing (201)
Drug shortages (31)
Duchenne muscular dystrophy (287)
Earnings (93079)
Editorial (67)
Employer branding (22)
Employer resources (154)
Events (121832)
Executive appointments (1098)
FDA (20318)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (34)
Funding (1739)
Gene editing (234)
Generative AI (56)
Gene therapy (726)
GLP-1 (1067)
Government (4748)
Grass and pollen (7)
Guidances (408)
Healthcare (19061)
HIV (80)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (290)
Immuno-oncology (94)
Indications (197)
Infectious disease (3095)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (293)
Interviews (323)
IPO (16854)
IRA (50)
Job creations (3694)
Job search strategy (1440)
JPM (58)
Kidney cancer (19)
Labor market (102)
Layoffs (568)
Leadership (39)
Legal (7980)
Liver cancer (100)
Longevity (33)
Lung cancer (769)
Lymphoma (431)
Machine learning (61)
Management (59)
Manufacturing (1063)
MASH (195)
Medical device (13953)
Medtech (14080)
Mergers & acquisitions (20316)
Metabolic disorders (1514)
mRNA (208)
Multiple sclerosis (191)
NASH (17)
Neurodegenerative disease (421)
Neuropsychiatric disorders (105)
Neuroscience (3336)
Neurotech (1)
NextGen: Class of 2026 (6547)
Non-profit (4545)
Now hiring (78)
Obesity (706)
Opinion (288)
Ovarian cancer (223)
Pain (259)
Pancreatic cancer (306)
Parkinson's disease (366)
Partnered (33)
Patents (601)
Patient recruitment (684)
Peanut (62)
People (60335)
Pharmaceutical (69)
Pharmacy benefit managers (32)
Phase 1 (22404)
Phase 2 (31677)
Phase 3 (23446)
Pipeline (8887)
Policy (319)
Postmarket research (2575)
Preclinical (9563)
Press Release (64)
Prostate cancer (305)
Psychedelics (54)
Radiopharmaceuticals (335)
Rare diseases (1085)
Real estate (6061)
Recruiting (71)
Regulatory (25620)
Reports (56)
Research institute (2427)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (22)
RSV (88)
Schizophrenia (178)
Series A (289)
Series B (214)
Service/supplier (11)
Sickle cell disease (112)
Special edition (24)
Spinal muscular atrophy (166)
Sponsored (48)
Startups (3687)
State (2)
Stomach cancer (18)
Supply chain (127)
Tariffs (87)
The Weekly (62)
Vaccines (1101)
Venture capital (111)
Weight loss (452)
Women's health (128)
Worklife (20)
Date
Today (128)
Last 7 days (741)
Last 30 days (3591)
Last 365 days (30456)
2026 (13018)
2025 (30428)
2024 (35553)
2023 (40470)
2022 (51633)
2021 (56241)
2020 (54469)
2019 (46897)
2018 (35310)
2017 (32505)
2016 (31948)
2015 (38016)
2014 (31842)
2013 (26766)
2012 (28943)
2011 (29608)
2010 (27666)
Location
Africa (751)
Alabama (98)
Alaska (7)
Arizona (351)
Arkansas (15)
Asia (40685)
Australia (6625)
California (13396)
Canada (3795)
China (1390)
Colorado (573)
Connecticut (582)
Delaware (412)
Europe (88790)
Florida (2030)
Georgia (428)
Hawaii (3)
Idaho (62)
Illinois (1058)
India (91)
Indiana (603)
Iowa (23)
Japan (542)
Kansas (131)
Kentucky (50)
Louisiana (43)
Maine (76)
Maryland (1608)
Massachusetts (9619)
Michigan (366)
Minnesota (728)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (143)
New Hampshire (84)
New Jersey (3530)
New Mexico (30)
New York (3524)
North Carolina (1756)
North Dakota (9)
Northern California (6717)
Ohio (399)
Oklahoma (23)
Oregon (42)
Pennsylvania (2692)
Puerto Rico (30)
Rhode Island (50)
South America (1125)
South Carolina (86)
South Dakota (2)
Southern California (5286)
Tennessee (214)
Texas (2135)
United States (47439)
Utah (398)
Vermont (1)
Virginia (328)
Washington D.C. (80)
Washington State (1083)
West Virginia (4)
Wisconsin (130)
Wyoming (2)
739,144 Results for "asklepios biopharmaceutical inc askbio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)
May 11, 2026
·
9 min read
Press Releases
AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure
April 1, 2026
·
9 min read
Press Releases
AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)
January 8, 2026
·
9 min read
Press Releases
First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease
September 23, 2025
·
12 min read
Press Releases
AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure
October 22, 2025
·
8 min read
Press Releases
AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
September 18, 2025
·
10 min read
Drug Development
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure
Bayer AG and Asklepios BioPharmaceutical, Inc. announced that the first patient has been randomized in GenePHIT, a Phase II trial of AB-1002 for the treatment of congestive heart failure.
February 16, 2024
·
10 min read
Drug Development
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
Asklepios BioPharmaceutical, Inc. (AskBio) today announced that the first patient has been randomized at the Ohio State University Wexner Medical Center in the Phase 1 REGENERATE MSA-101 clinical trial of AB-1005, a gene therapy being developed as a treatment for multiple system atrophy-parkinsonian type (MSA-P).
November 17, 2023
·
10 min read
Business
ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform
ReCode Therapeutics announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio).
January 9, 2023
·
5 min read
Press Releases
Servier completes the acquisition of Day One Biopharmaceuticals
April 23, 2026
·
2 min read
1 of 73,915
Next
